Home / TRAIL R2/TNFRSF10B / Human TRAIL R2/TNFRSF10B Antibody

Human TRAIL R2/TNFRSF10B Antibody

Catalog #: MAB6311
24 Citations Datasheet
Catalog # Availability Size / Price Qty
MAB6311
MAB6311-SP
Detection of Human TRAILR2/TNFRSF10B by Flow Cytometry
1 Image
Product Details
Citations (24)
FAQs
Supplemental Products
Reviews
Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human TRAIL R2/TNFRSF10B Antibody Summary

Species Reactivity
Human
Specificity
Detects human TRAIL R2 in direct ELISAs and Western blots. In direct ELISAs, does not cross-react with recombinant human (rh) TRAIL R1, rhTRAIL R3, rhTRAIL R4, or recombinant mouse TRAIL R2.
Source
Monoclonal Mouse IgG2B Clone # 71908
Purification
Protein A or G purified from hybridoma culture supernatant
Immunogen
Mouse myeloma cell line NS0-derived recombinant human TRAIL R2/TNFRSF10B
Ile56-Glu182
Accession # O14763
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Flow Cytometry
2.5 µg/106 cells
MDA‑MB‑231 human breast cancer cell line
CyTOF-ready
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
 

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Flow Cytometry Detection of Human TRAILR2/TNFRSF10B by Flow Cytometry View Larger

Detection of Human TRAILR2/TNFRSF10B by Flow Cytometry Flow cytometry studies of scFv-Fc-scTRAIL molecules and Fc-scTRAIL on Colo205 and HCT116 cells(A) Expression levels of EGFR, HER2, HER3, EpCAM, and TRAIL-receptors were investigated after treatment of the cells with medium or 250 ng/ml BZB for 16 h. (B) Serial dilutions of the molecules were analyzed. (C) 20 nM scTRAIL units were analyzed after preincubation of the cells with PBA or a 200-fold molar excess of the respective blocking antibody. Binding of Fc-scTRAIL was measured in the presence of all blocking antibodies separately and is here represented as the mean of blocking with all different antibodies. Bound molecules were detected via anti-FLAG-PE. relative MFI, relative median fluorescence intensity. Pairwise comparisons were performed by unpaired t test (two-tailed; *P < 0.05; **P < 0.01; ***P < 0.001; ns, P > 0.05). Image collected and cropped by CiteAb from the following publication (https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.24379), licensed under a CC-BY license. Not internally tested by R&D Systems.

Preparation and Storage

Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS.
Loading...
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: TRAIL R2/TNFRSF10B

Human TRAIL R2, also known as DR5 and TRICK 2, is a type 1, TNF R family, membrane protein which is a receptor for TRAIL (APO2 ligand). In the new TNF superfamily nomenclature, TRAIL R2 is referred to as TNFRSF10B. TRAIL R2 cDNA encodes a 440 amino acid residue precursor protein containing extracellular cysteine-rich domains, a transmembrane domain and a cytoplasmic death domain. Among TNF receptor family proteins, TRAIL R2 is most closely related to TRAIL R1/DR4, sharing 55% amino acid sequence identity. Binding of trimeric TRAIL to TRAIL R2 induces apoptosis. The induction of apoptosis likely requires oligomerization of the receptor. The human TRAIL R2/Fc chimera neutralizes the ability of TRAIL to induce apoptosis. Besides TRAIL R2, an additional TRAIL R1/DR4, which tranduces apoptosis signaling, and two TRAIL decoy receptors, which antagonize TRAIL-induced apoptosis, have been reported.

References
  1. Chaudhary, P.M. et al. (1997) Immunity 7:821.
  2. Walczak, H. et al. (1997) EMBO J. 16:5386.
  3. Golstein, P. (1997) Curr. Biol. 7:R750.
Long Name
TRAIL Receptor 2
Entrez Gene IDs
8795 (Human); 21933 (Mouse)
Alternate Names
CD262 antigen; CD262; death domain containing receptor for TRAIL/Apo-2L; Death receptor 5; DR5; DR5TRICK2B; Fas-like protein; KILLER/DR5; KILLERapoptosis inducing protein TRICK2A/2B; TNF-related apoptosis-inducing ligand receptor 2; TNFRSF10B; TRAIL R2; TRAIL receptor 2; TRAILR2; TRAIL-R2apoptosis inducing receptor TRAIL-R2; TRAILR2cytotoxic TRAIL receptor-2; TRICK2; TRICK2A; TRICKB; tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9; ZTNFR9

Product Datasheets

You must select a language.

x
Product Datasheet

Citations for Human TRAIL R2/TNFRSF10B Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

24 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Low-Level Endothelial TRAIL-Receptor Expression Obstructs the CNS-Delivery of Angiopep-2 Functionalised TRAIL-Receptor Agonists for the Treatment of Glioblastoma
    Authors: Nivetha Krishna Moorthy, Oliver Seifert, Stephan Eisler, Sara Weirich, Roland E. Kontermann, Markus Rehm et al.
    Molecules
  2. Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist
    Authors: C Boccellato, E Kolbe, N Peters, V Juric, G Fullstone, M Verreault, A Idbaih, MLM Lamfers, BM Murphy, M Rehm
    Cell Death & Disease, 2021-06-24;12(7):647.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  3. CD154 inhibits death of T cells via a Cis interaction with the alpha5beta1 integrin
    Authors: M Bachsais, S Salti, K Zaoui, GS Hassan, F Aoudjit, W Mourad
    PLoS ONE, 2020-08-03;15(8):e0235753.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry, ICC
  4. Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroids
    Authors: D Stöhr, JO Schmid, TB Beigl, A Mack, DS Maichl, K Cao, B Budai, G Fullstone, RE Kontermann, TE Mürdter, SWG Tait, C Hagenloche, N Pollak, P Scheurich, M Rehm
    Cell Death Differ., 2020-05-20;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  5. Potential Role of CD133 Expression in the Susceptibility of Human Liver Cancer Stem-Like Cells to TRAIL
    Authors: SH Lee, SK Hyun, HB Kim, CD Kang, SH Kim
    Oncol. Res., 2016-10-27;24(6):495-509.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  6. Interferon-beta inhibits glioma angiogenesis through downregulation of vascular endothelial growth factor and upregulation of interferon inducible protein 10.
    Authors: Takano S, Ishikawa E, Matsuda M, Yamamoto T, Matsumura A
    Int J Oncol, 2014-08-25;45(5):1837-46.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  7. Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes.
    Authors: Neumann S, Hasenauer J, Pollak N, Scheurich P
    J Biol Chem, 2014-04-24;289(23):16576-87.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  8. TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells.
    Authors: Tang X, Lu J, Tu H, Huang K, Fu R, Cao G, Huang M, Cheng L, Dai L, Zhang L
    Anticancer Res, 2014-02-01;34(2):729-34.
    Species: Rat
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  9. Crosstalk between mitochondrial ROS and depolarization in the potentiation of TRAIL-induced apoptosis in human tumor cells.
    Authors: Suzuki-Karasaki M, Ochiai T, Suzuki-Karasaki Y
    Int J Oncol, 2013-12-10;44(2):616-28.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  10. Exosomes secreted by human placenta carry functional Fas ligand and TRAIL molecules and convey apoptosis in activated immune cells, suggesting exosome-mediated immune privilege of the fetus.
    Authors: Stenqvist A, Nagaeva O, Baranov V, Mincheva-Nilsson L
    J Immunol, 2013-11-01;191(11):5515-23.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  11. Casticin potentiates TRAIL-induced apoptosis of gastric cancer cells through endoplasmic reticulum stress.
    Authors: Zhou Y, Tian L, Long L, Quan M, Liu F, Cao J
    PLoS ONE, 2013-03-11;8(3):e58855.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  12. The transmembrane domains of TNF-related apoptosis-inducing ligand (TRAIL) receptors 1 and 2 co-regulate apoptotic signaling capacity.
    Authors: Neumann S, Bidon T, Branschadel M, Krippner-Heidenreich A, Scheurich P, Doszczak M
    PLoS ONE, 2012-08-03;7(8):e42526.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  13. TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells.
    Cancer Gene Ther., 2012-07-06;19(9):652-8.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  14. Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity
    Authors: M Siegemund, N Pollak, O Seifert, K Wahl, K Hanak, A Vogel et al.
    Cell Death & Disease
  15. Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL).
    Authors: Zauli G, Rimondi E, Celeghini C, Milani D, Secchiero P
    J. Cell. Physiol., 2010-02-01;222(2):357-64.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  16. Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients.
    Authors: Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Mullauer L, Quendler H, Kohrgruber N, Stingl G
    Blood, 2009-08-18;114(18):3854-63.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  17. Differential responses of FLIPLong and FLIPShort-overexpressing human myeloid leukemia cells to TNF-alpha and TRAIL-initiated apoptotic signals.
    Authors: Seal S, Hockenbery DM, Spaulding EY, Kiem HP, Abbassi N, Deeg HJ
    Exp. Hematol., 2008-10-05;36(12):1660-72.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  18. Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms.
    Authors: Shankar S, Chen Q, Ganapathy S, Singh KP, Srivastava RK
    Mol. Cancer Ther., 2008-08-01;7(8):2328-38.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  19. Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
    Authors: Barbarotto E, Corallini F, Rimondi E, Fadda R, Mischiati C, Grill V, Vaccarezza M, Celeghini C
    J. Cell. Biochem., 2008-05-15;104(2):595-605.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  20. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
    Authors: Toscano F, Fajoui ZE, Gay F, Lalaoui N, Parmentier B, Chayvialle JA, Scoazec JY, Micheau O, Abello J, Saurin JC
    Oncogene, 2008-03-17;27(30):4161-71.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  21. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
    Authors: Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B, Weller M
    Cell Death Differ., 2008-01-18;15(4):718-729.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  22. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage.
    Authors: Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, Lampertico P, Das A, Lopes AR, Borrow P, Williams K, Humphreys E, Afford S, Adams DH, Bertoletti A, Maini MK
    J. Exp. Med., 2007-03-12;204(3):667-80.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  23. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma.
    Authors: Singh TR, Shankar S, Srivastava RK
    Oncogene, 2005-07-07;24(29):4609-23.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  24. Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy
    Authors: JD Yoo, SM Bae, J Seo, IS Jeon, SMP Vadevoo, SY Kim, IS Kim, B Lee, S Kim
    Sci Rep, 2020-11-17;10(1):19997.

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Human TRAIL R2/TNFRSF10B Antibody

There are currently no reviews for this product. Be the first to review Human TRAIL R2/TNFRSF10B Antibody and earn rewards!

Have you used Human TRAIL R2/TNFRSF10B Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review